ACO-SWITCHAcoramidis Impact on Serum Transthyretin Levels in ATTR-CM Patients Previously Treated with Tafamidis

This study focuses on a condition called Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM), where a protein called Transthyretin (TTR) breaks down and forms harmful clumps in the heart, affecting its ability to pump blood effectively. This can be due to aging (wild-type ATTR-CM) or genetics (variant ATTR-CM). The study uses a drug called acoramidis, which helps stabilize the TTR protein to prevent it from breaking down and forming these clumps. The main goal of this research is to understand how switching from another similar drug, tafamidis, to acoramidis affects the levels of TTR in the blood of adults with ATTR-CM who were previously treated with tafamidis. During the study, participants will continue taking tafamidis during the screening period, and then switch to acoramidis, taking two tablets twice daily by mouth for up to 6 months. The change in TTR protein levels in the blood will be measured after 6 months of treatment with acoramidis, or earlier if a participant stops the treatment before reaching that point. Participants will have regular check-ups, including heart function tests, blood and urine samples, and health monitoring. The study involves 9 check-ins, with 2 visits to the study site, 6 home visits by a study nurse, and a final check-in by phone. Each participant may be involved in the study for about 8 months.